All In Biotech

Drug Trial Radar · NCT05697809

Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, Efficacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres®) Using the Oxulumis® Illuminated Microcatheterization Device Compared With Intravitreal Dexamethasone Implant (OZURDEX®) in Subjects With Diabetic Macular Edema (OXEYE)

Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

3

Actual

Start

Aug 7, 2023

Primary completion

Dec 5, 2024

Study completion Dec 5, 2024

Sponsor

Lead sponsor
Oxular LimitedIndustry
Sponsor type
Industry
First posted
Jan 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis® illuminated microcatheterization device compared with intravitreal dexamethasone implant (OZURDEX®) in subjects with diabetic macular edema.

Conditions

  • Diabetic Macular Edema

Interventions

  • OXU-001Drug

    Suprachoroidal sustained release dexamethasone acetate

  • Semi-automated suprachoroidal illuminated microcatheterDevice

    Ophthalmic administration device

  • Ozurdex® Ophthalmic Intravitreal ImplantDrug

    Ophthalmic dexamethasone intravitreal implant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and Severity of Ocular and Systemic Treatment Emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special InterestTime frame: Day 0 up to Week 52
  2. Frequency and Severity of Treatment-emergent Adverse Device EffectsTime frame: Day 0 up to Week 52

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • Blue Ocean Clinical Research West

    Clearwater, Florida

  • University Retina and Macula Associates

    Oak Forest, Illinois

  • Retina Consultants of Minnesota

    Minneapolis, Minnesota

  • Sierra Eye Associates

    Reno, Nevada

  • Retina Consultants of Texas

    Houston, Texas

  • Valley Retina Institute, PA

    McAllen, Texas

  • Retinal Consultants of Texas - San Antonio

    San Antonio, Texas

  • Emmanuelli Research and Development Center, LLC

    Arecibo, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.